Systems Neurobiology Research Unit, University of Stuttgart, Stuttgart, Germany.
Preclinical Laboratory, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich (PUK) and University of Zurich (UZH), Zurich, Switzerland.
Neuropharmacology. 2022 Aug 1;213:109078. doi: 10.1016/j.neuropharm.2022.109078. Epub 2022 May 10.
Apathy, deficiency of motivation including willingness to exert effort for reward, is a common symptom in many psychiatric and neurological disorders, including depression and schizophrenia. Despite improved understanding of the neurocircuitry and neurochemistry underlying normal and deficient motivation, there is still no approved pharmacological treatment for such a deficiency. GPR139 is an orphan G protein-coupled receptor expressed in brain regions which contribute to the neural circuitry that controls motivation including effortful responding for reward, typically sweet gustatory reward. The GPR139 agonist TAK-041 is currently under development for treatment of negative symptoms in schizophrenia which include apathy. To date, however, there are no published preclinical data regarding its potential effect on reward motivation or deficiencies thereof. Here we report in vitro evidence confirming that TAK-041 increases intracellular Ca mobilization and has high selectivity for GPR139. In vivo, TAK-041 was brain penetrant and showed a favorable pharmacokinetic profile. It was without effect on extracellular dopamine concentration in the nucleus accumbens. In addition, TAK-041 did not alter the effort exerted to obtain sweet gustatory reward in rats that were moderately food deprived. By contrast, TAK-041 increased the effort exerted to obtain sweet gustatory reward in mice that were only minimally food deprived; furthermore, this effect of TAK-041 occurred both in control mice and in mice in which deficient effortful responding was induced by chronic social stress. Overall, this study provides preclinical evidence in support of GPR139 agonism as a molecular target mechanism for treatment of apathy.
淡漠,动机不足包括为奖励付出努力的意愿,是许多精神和神经障碍的常见症状,包括抑郁症和精神分裂症。尽管对正常和缺乏动机的神经回路和神经化学有了更好的理解,但仍然没有批准的药物治疗这种缺乏。GPR139 是一种孤儿 G 蛋白偶联受体,在大脑区域表达,这些区域有助于控制动机的神经回路,包括为奖励付出努力的反应,通常是美味的味觉奖励。GPR139 激动剂 TAK-041 目前正在开发用于治疗精神分裂症的阴性症状,包括淡漠。然而,迄今为止,尚无关于其对奖励动机或缺乏奖励动机的潜在影响的已发表的临床前数据。在这里,我们报告了体外证据,证实 TAK-041 增加细胞内 Ca 动员,并对 GPR139 具有高选择性。在体内,TAK-041 具有脑穿透性,并表现出有利的药代动力学特征。它对伏隔核中的细胞外多巴胺浓度没有影响。此外,TAK-041 不会改变中度禁食的大鼠获得美味味觉奖励的努力程度。相比之下,TAK-041 增加了仅轻度禁食的小鼠获得美味味觉奖励的努力程度;此外,TAK-041 的这种作用既发生在对照小鼠中,也发生在慢性社会压力导致缺乏努力反应的小鼠中。总的来说,这项研究提供了临床前证据,支持 GPR139 激动剂作为治疗淡漠的分子靶机制。